Product Pipeline
Lycera is developing a robust pipeline of selective, oral immunomodulators targeting novel autoimmune pathways. The company has two first-in-class programs that are rapidly advancing toward the clinic. Lycera is on track to begin clinical trials in 2012 with its bioenergetics program focused on regulating the pathways that cells use to make and utilize energy.
